# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Novo Nordisk's Saxenda study published in JAMA Network Open reveals significant declines in bone density among patients, ra...
Eli Lilly collaborates with Microsoft-backed OpenAI to leverage generative AI for developing novel antimicrobials targeting dru...
Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly and Co (NYSE:LLY) with a Overweight and maintains $885 price target.
Eli Lilly and Company (NYSE:LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generativ...
Truist Securities analyst Srikripa Devarakonda reiterates Eli Lilly and Co (NYSE:LLY) with a Buy and raises the price target...
Eli Lilly and Co (NYSE: LLY) shares are moving higher Monday following the release of positive Phase 3 trial results for its we...
ResMed stock is trading lower Monday after Eli Lilly and Company released data from a clinical trial in regards to the treatmen...